News Conference News ACC 2025 FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints While inconsistent dosing could have played a role, it still may be possible to identify the patients most likely to see benefit. L.A. McKeown April 03, 2025
Presentation ACC 2025 FAIR-HF2 Trial: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality Presenter: Stefan D. Anker March 30, 2025
Presentation ACC 2025 The MIGHTy-Heart Randomized Clinical Trial Presenter: Ruth Masterson Creber March 30, 2025
Presentation ACC 2025 Liberal Fluid Intake versus Fluid Restriction in Chronic Heart Failure: The FRESH-UP Study Presenter: Roland R. Van Kimmenade March 30, 2025
Presentation ACC 2025 Dapagliflozin after Transcatheter Aortic Valve Implantation Presenter: Sergio Raposeiras-Roubin March 29, 2025
Presentation THT 2025 Voice of the Heart: SQ ICM for Heart Failure Using ECG and Heart Sounds as Biomarkers Presenter: Jaeson Bang February 13, 2025
News Daily News Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM By L.A. McKeown April 15, 2025
News Conference News ACC 2025 FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints By L.A. McKeown April 03, 2025
News Conference News ACC 2025 Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP By Michael O'Riordan April 01, 2025